ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 0920

Retention Rate and Safety of Biologic or Targeted Synthetic Disease Modifying Anti-rheumatic Drugs (DMARDs) in Patients with Rheumatoid Arthritis Associated with Interstitial Lung Disease: Results from the KOBIO Registry
Abstract Number: 0921

Effects of Methotrexate on the Liver Function and Disease Activity of Newly Diagnosed RA Patients Depending on the Cardiometabolic Profile
Abstract Number: 0922

Alteration of the Cardiometabolic and Cardiovascular Proteome in Rheumatoid Arthritis. Modulation by Methotrexate and Tofacitinib
Abstract Number: 0923

Identification of Cell-Specific DNA Methylation Changes Associated with MTX Treatment Response in Rheumatoid Arthritis
Abstract Number: 0924

Vitamin B12 Status and Hyperhomocysteinemia in Patients with Rheumatoid Arthritis Treated with Methotrexate and Folic Acid
Abstract Number: 0925

Impact of Initiating Biologic and Targeted Synthetic Disease-Modifying Antirheumatic Drugs on Pain Medication Use in Patients with Rheumatoid Arthritis
Abstract Number: 0926

Methotrexate Polyglutamates Exposure – Response Modelling in a Large Cohort of Rheumatoid Arthritis Patients Starting Methotrexate
Abstract Number: 0927

Review of 167,990 Same Day RAPID3, CDAI Scores for 61,312 Patients Receiving DMARD Treatment for Rheumatoid Arthritis; Evaluations of Disease Assessments and Treatment Discontinuation
Abstract Number: 0928

Use of Disease Modifying Anti-rheumatic Drugs and Risk of Multiple Myeloma in US Veterans with Rheumatoid Arthritis
Abstract Number: 0929

Severe Low-Dose Methotrexate Toxicity in Elderly Patients with Inflammatory Rheumatic Diseases
Abstract Number: 0930

Delayed Response to Methotrexate Treatment in Rheumatoid Arthritis Patients Receiving Folic Acid Supplementation
Abstract Number: 0931

Rituximab versus Leflunomide in Combination with Methotrexate in Patients with Active Rheumatoid Arthritis Despite Methotrexate Treatment- an Open Label Randomized Controlled Trial
Abstract Number: 0932

Accelerated Waning of Protective Immunity After SARS-CoV-2 mRNA Vaccination in Patients Treated with Biological and Targeted Synthetic Disease Modifying Antirheumatic Drugs
Abstract Number: 0933

Exploratory Study of the Usefulness of TNFAIP3 Genetic Variants in Predicting Response to Methotrexate in Early Arthritis Patients
Abstract Number: 0934

Impact of Tapering Targeted Therapy on Disease Activity Is Different Based on Concomitant Methotrexate Use in Patients with Rheumatoid Arthritis: A Nationwide Cohort Study

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].